Plans for Extended Long-Term Safety Evaluation

• Approximately 800 patients in ongoing safety-extension studies

• Alefacept safety registry

  • powered to specifically evaluate increase in risk of adverse events of interest

Previous slide

Next slide

Back to first slide

View graphic version